Eagle Health Investments’s United Therapeutics UTHR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q1
Sell
-21,802
Closed -$7.69M 21
2024
Q4
$7.69M Sell
21,802
-32,297
-60% -$11.9M 1.89% 14
2024
Q3
$19.4M Sell
54,099
-113,400
-68% -$38.3M 3.67% 13
2024
Q2
$53.4M Sell
167,499
-12,000
-7% -$3.18M 9.36% 1
2024
Q1
$41.2M Buy
179,499
+8,661
+5% +$1.95M 7.66% 4
2023
Q4
$37.6M Hold
170,838
7.63% 6
2023
Q3
$38.6M Hold
170,838
8.5% 4
2023
Q2
$37.7M Buy
170,838
+39,600
+30% +$8.77M 7.05% 4
2023
Q1
$29.4M Hold
131,238
5.72% 7
2022
Q4
$36.5M Sell
131,238
-9,500
-7% -$2.4M 8.42% 3
2022
Q3
$29.5M Sell
140,738
-18,500
-12% -$4.14M 6.76% 4
2022
Q2
$37.5M Hold
159,238
8.75% 3
2022
Q1
$28.6M Buy
159,238
+5,800
+4% +$1.1M 7.04% 4
2021
Q4
$33.2M Buy
153,438
+55,400
+57% +$10.9M 8.08% 3
2021
Q3
$18.1M Hold
98,038
5.74% 6
2021
Q2
$17.6M Buy
98,038
+4,938
+5% +$940K 6.03% 6
2021
Q1
$15.6M Buy
93,100
+23,100
+33% +$3.85M 6.11% 7
2020
Q4
$10.6M Buy
+70,000
New +$9.19M 6.8% 7

Other funds holding UTHR

Eagle Health Investments's UTHR Position: Q1 2025 in Review

Eagle Health Investments sold out of United Therapeutics (UTHR) in Q1 2025, closing a stake of 21,802 shares — an estimated $7.69M sold.

Eagle Health Investments first reported a position in UTHR in Q4 2020 and held it in 17 quarters. The position peaked at $53.4M in Q2 2024. 671 funds tracked by Wall St. Rank hold UTHR as of Q1 2025.

  • Eagle Health Investments reported no remaining United Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Eagle Health Investments sold 21,802 United Therapeutics shares in Q1 2025, an estimated $7.69M.
  • Eagle Health Investments first reported a position in United Therapeutics in Q4 2020 and held it in 17 quarters.
  • Eagle Health Investments's United Therapeutics position peaked at $53.4M in Q2 2024.
  • 671 funds tracked by Wall St. Rank held United Therapeutics as of Q1 2025.

Based on Eagle Health Investments's 13F filing for Q1 2025, filed 12 May 2025.